Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03118466
Recruitment Status : Recruiting
First Posted : April 18, 2017
Last Update Posted : June 26, 2019
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
Andrew Mark Brunner, MD, Massachusetts General Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : September 30, 2024